Data Safety Monitoring Board recommends continuation of phase 1/2 clinical trial with Sernova’s Cell Pouch System™ in patients with Type-1 Diabetes
Sernova Corp., a clinical- stage company and leader in regenerative medicine cell therapeutics, is pleased to announce that the Data Safety Monitoring Board (“DSMB”) has completed the third annual review of Sernova’s ongoing Phase 1/2 clinical study “Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch for Clinical Islet Transplantation” in patients with Type-1 Diabetes…